Compound research hub

SLU-PP-332: Research, Handling and Batch Documentation

SLU-PP-332 is a small molecule, not a peptide: a pan-agonist of the estrogen-related receptors studied in mice for the aerobic exercise gene programme, with no human trial initiated or planned.

Part of Volta's weight management research peptides catalogue.

Identity and research status

Also referred to as: ERR Agonist, Exercise Pill, Pan-ERR Agonist
Class: Small synthetic molecule, not a peptide
Molecular Target: Estrogen-related receptors ERR alpha, beta and gamma
Selectivity: Pan-agonist across all three ERR subtypes
Receptor Family: Orphan nuclear receptors. They do not bind estrogen despite the name
Successor Compound: SLU-PP-915, an orally active analogue from the same programme
Functional Class: Exercise mimetic, meaning it engages part of the exercise transcriptional programme
Regulatory Status: Investigational. Not approved in any jurisdiction
Development Stage: Preclinical. No human trials
Doping Status: Analytical detection methods have been published in the doping control literature
Appearance: Solid, typically supplied as a powder

Evidence level: Animal/Preclinical Only (grade D)

Regulatory status: Preclinical only. Published murine studies from Washington University. No human trials planned or initiated.

Evidence grades describe the published literature on the compound, not a property of the material Volta supplies, and are not a statement that any use is approved. See how these grades are assigned.

Mechanism, in brief

SLU-PP-332 is not a peptide. It is a small synthetic molecule, and it sits in this catalogue alongside peptides for commercial rather than chemical reasons. Saying so first matters, because almost everything this catalogue says about handling, purity determination and certificate interpretation is written for peptides and does not transfer to a small molecule.

ERR binding. Pan-agonism across estrogen-related receptors alpha, beta and gamma, which are orphan nuclear receptors that do not bind estrogen despite the name.
Transcriptional activation. ERRs are constitutively active transcription factors; an agonist increases their activity at genes controlling oxidative metabolism.
Mitochondrial biogenesis. Downstream gene programmes include mitochondrial biogenesis and fatty acid oxidation, which are the same pathways endurance exercise engages.
Skeletal muscle oxidative capacity. Reported increases in muscle oxidative capacity and aerobic function, which is the basis of the exercise mimetic framing.
Metabolic consequences. Rodent work reports improvement in features of metabolic syndrome, consistent with increased oxidative metabolism rather than with appetite or insulin secretion effects.

The full research write-up, including the findings behind each claim and the model each came from, is on the SLU-PP-332 5mg 5mg page.

Vial sizes available

Every size of SLU-PP-332 Volta lists, in stock or not. Each is a separate catalogue page with its own batch number and specification table.

SLU-PP-332 5mg 5mgBatch #: VPSP5100
Restocking

Purity and batch documentation

Volta's release specification is >99% (HPLC). That is a threshold we set. >99% is the specification every batch is released to. The figure on a certificate is what a laboratory measured for one lot.

No third-party certificate has been published for SLU-PP-332yet. The certificates Volta does publish, with the laboratory's own verification link on each, are in the certificate archive.

the complete batch history dataset how each batch is tested laboratories that test peptides independently

Research on SLU-PP-332

Concentrations used in the literature

the concentrations used in the published murine work

Comparisons

Handling and stability

Laboratory guides

Calculators

Regulatory context

United States: Research compound. No FDA filing. Not approved for any use.
WADA: Not yet listed but likely to be prohibited if it reaches clinical development.
Global: No regulatory status anywhere.

Primary sources

Billon C, Schoepke E, Undru A, et al.. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics (2024). PMID 37739806
Okda HE, Zhao P, et al.. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor pharmacology. International Journal of Biological Macromolecules (2026). PMID 41850449
Billon C, Appourchaux K, et al.. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. Journal of Pharmacology and Experimental Therapeutics (2026). PMID 41421047
Möller T, Krug O, et al.. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists. Rapid Communications in Mass Spectrometry (2026). PMID 41588687
de Souza-Lima J, Astrosa-Martin BD, et al.. Pharmacological Activation of ERR alpha, beta and gamma as an Exercise Mimetic: Potential Therapeutic Applications. Revista Medica de Chile (2026). PMID 42024694
Bonanni R, Falvino A, et al.. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity. Frontiers in Physiology (2025). PMID 40692696

More weight management research peptides

SLU-PP-332 sits in Volta's weight management research peptides catalogue, alongside the other compounds studied in this area. The whole range is on the full research catalogue, and the library of comparisons and guides is under peptide research.